FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian CancerCLINICAL CANCER RESEARCHIF10.22023-05-2232OA
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell CarcinomaCLINICAL CANCER RESEARCHIF10.22022-02-0128OA
FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast CancerCLINICAL CANCER RESEARCHIF10.22021-12-1629OA
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast CancerCLINICAL CANCER RESEARCHIF10.22021-03-2288OA
FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast CancerCLINICAL CANCER RESEARCHIF10.22020-11-132PREAI
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast CancerCLINICAL CANCER RESEARCHIF10.22020-11-09105OAAI